National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Cemiplimab (Libtayo®). HTA ID: 21007

Cemiplimab (Libtayo®) is indicated as monotherapy for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiation.

 

NCPE Assessment Process Complete
Rapid review commissioned 15/03/2021
Rapid review completed 23/03/2021
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of cemiplimab (Libtayo®) compared with the current standard of care.